Biotech stocks have been some of the most reliable capital-appreciation vehicles in the entire market for the past two decades. As proof, biotech equities such as CRISPR Therapeutics, Moderna, Novavax, Ocugen, and Vertex Pharmaceuticals -- just to name a few -- have all made their early shareholders market-crushing gains. Not all biotech stocks are cut from the same cloth, however.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting